InVivo Therapeutics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. InVivo Therapeutics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. InVivo Therapeutics Holdings's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $8.92 Mil.
InVivo Therapeutics Holdings's debt to equity for the quarter that ended in Sep. 2023 was 0.00.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for InVivo Therapeutics Holdings's Debt-to-Equity or its related term are showing as below:
NVIVQ'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.17 Med: 0.08 Max: 0.33
Current: 0.09
During the past 13 years, the highest Debt-to-Equity Ratio of InVivo Therapeutics Holdings was 0.33. The lowest was -0.17. And the median was 0.08.
InVivo Therapeutics Holdings Debt-to-Equity Historical Data
The historical data trend for InVivo Therapeutics Holdings's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
InVivo Therapeutics Holdings Annual Data
|
|
Trend |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
| Debt-to-Equity |
|
|
|
|
|
|
0.01 |
0.24 |
0.05 |
0.07 |
0.06 |
|
InVivo Therapeutics Holdings Quarterly Data
|
|
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
| Debt-to-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.10 |
0.06 |
0.06 |
0.07 |
- |
Competitive Comparison
For the Biotechnology subindustry, InVivo Therapeutics Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InVivo Therapeutics Holdings Debt-to-Equity Distribution
For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where InVivo Therapeutics Holdings's Debt-to-Equity falls into.
InVivo Therapeutics Holdings Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
InVivo Therapeutics Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as
InVivo Therapeutics Holdings's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Business Description
Traded in Other Exchanges
Address
One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139
InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.
Executives
| Brice Foose |
10 percent owner |
236 SILENT MEADOW DRIVE, LAKE ST. LOUIS MO 63367 |
| Daniel R Marshak |
director |
C/O CAMBREX CORP, ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ 07073 |
| Christina Morrison |
director |
ARAMARK, 1101 MARKET STREET, PHILADELPHIA PA 19107 |
| Richard M. Toselli |
director, officer: CEO and CMO |
C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139 |
| Richard Christopher |
officer: Chief Financial Officer |
C/O LUCID, INC., 50 METHODIST HILL DR, SUITE 1000, ROCHESTER NY 14623 |
| C Ann Merrifield |
director |
|
| Bob Rosenthal |
director |
20 NEWBURY ST, BOSTON MA 02116 |
| Heather Hamel |
officer: Chief Legal Officer and GC |
ONE KENDALL SQUARE, BUILDING 1400 WEST, FLOOR 4, CAMBRIDGE MA 02139 |
| Jeffrey Modestino |
officer: See Remarks |
C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14403, CAMBRIDGE MA 02139 |
| Christopher Mcnulty |
officer: Chief Financial Officer |
C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139 |
| Melanie Golarz |
officer: Interim CFO |
C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139 |
| Jeffrey S. Hatfield |
director |
11080 ROSELLE STREET, SAN DIEGO CA 92121 |
| Pamela J Stahl |
officer: Chief Commercial Officer |
ONE KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139 |
| Richard John Roberts |
director |
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
| Masuoka K. Lorianne |
officer: Chief Medical Officer |
C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NVIVQ has been successfully added to your